For decades, millions of men with early prostate cancer have been placed on drug therapy to suppress their production of testosterone, despite such significant side effects as impotence, diabetes and bone loss. Now a large new analysis has concluded that so-called androgen deprivation therapy does not extend the lives of these patients.
“There are so many side effects associated with this therapy, and really little evidence to support its use,” said Dr. Grace L. Lu-Yao, a researcher at the Rutgers Cancer Institute of New Jersey and the lead author of the report, published on Monday in JAMA Internal Medicine. “I would say that for the majority of patients with localized prostate cancer, this is not a good option.”
Read more: http://well.blogs.nytimes.com/2014/07/14/study-discounts-testosterone-therapy-for-early-prostate-cancer/?_php=true&_type=blogs&_php=true&_type=blogs&_php=true&_type=blogs&module=Search&mabReward=relbias%3Ar%2C%7B%221%22%3A%22RI%3A6%22%7D&_r=2&